As IB does not influence eEF2K/eEF2 signalling or protein synthesis in primary CLL cells, our results suggest that a combination of IB with nelfinavir to target both BCR-mediated signalling and translation elongation may provide enhanced clinical benefit to CLL patients. Here, EEF2K is linked to B-cell chronic lymphocytic leukemia.